Loading stock data…
$70.72+2.41 (+3.52%)
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.
Sol-Gel Technologies Ltd. in the Healthcare sector is trading at $70.72 with a market capitalization of $235M. Wall Street consensus targets $152.50 (2 analysts), implying a +115.7% move over the next 12 months. The stock is currently 28% below its 52-week high of $97.97, remaining 3.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $591,000↑ | $108,000↓ | $696,000↑ | $400,000↓ | $17.26M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.16M↓ | -$3.85M↓ | -$3.41M↑ | -$6.29M↓ | $11.23M |
| Net Income | -$3.68M↑ | -$3.73M↓ | -$2.99M↑ | -$5.94M↓ | $11.61M |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The compan...